IQVIA HOLDINGS INC.
IQVIA Inc. said it raised full-year 2026 revenue guidance to US$17.28–US$17.48 billion, with Q3 outlook of US$4.32–US$4.39 billion, alongside reporting Q2 results and buyback activity. IQVIA also announced a collaboration with Medera Inc. on cardiac gene therapies and human-based drug discovery, linking IQVIA trial and platform capabilities to Medera programs.
IQVIA Holdings said it will expand its partnership with Medera to support cardiac gene therapies and human-based drug discovery using IQVIA’s clinical and regulatory infrastructure. The article also cites raised 2026 revenue guidance, Q2 results, and ongoing share repurchases. It discusses valuation, including a $232 fair value versus a $232.43 close and a DCF implying ~36% below cash-flow value.
STAUB W RICHARD (See Remarks) sold 5,500 shares of IQVIA HOLDINGS INC. (IQV) at $232.68 ($1.28M total) on 2026-08-03.
Over the past 7 days, alphai's AI scored 2 news stories mentioning IQV (IQVIA HOLDINGS INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent IQV coverage spans insider activity, financial news and earnings.
In the last 30 days, IQV insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($41.4M). The most active reporter was BOUSBIB ARI, See Remarks, with 6 filings.
Higher 2026 revenue guidance and a new gene-therapy alliance can support CRO demand and backlog-conversion expectations, partially offset by ongoing pricing pressure.
The Medera collaboration is incremental positive for IQVIA’s CRO/CDMO-like services demand, but the article frames it mainly alongside valuation debate rather than new financial guidance details.
This is a routine insider open-market sale with no stated 10b5-1 plan, but it does not disclose new company fundamentals.
This is a routine insider open-market sale under a Form 4, with no 10b5-1 plan and no stated reason, so it is more sentiment than fundamentals.
The deal reinforces IQVIA’s clinical services demand in gene therapy and human-based discovery, but it is not quantified in the article.
alphai scores every news story that mentions IQV with an AI model for sentiment and relevance, and aggregates insider trades from IQVIA HOLDINGS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
IQVIA Inc. said it raised full-year 2026 revenue guidance to US$17.28–US$17.48 billion, with Q3 outlook of US$4.32–US$4.39 billion, alongside reporting Q2 results and buyback activity. IQVIA also announced a collaboration with Medera Inc. on cardiac gene therapies and human-based drug discovery, linking IQVIA trial and platform capabilities to Medera programs.
6 min readIQVIA Holdings said it will expand its partnership with Medera to support cardiac gene therapies and human-based drug discovery using IQVIA’s clinical and regulatory infrastructure. The article also cites raised 2026 revenue guidance, Q2 results, and ongoing share repurchases. It discusses valuation, including a $232 fair value versus a $232.43 close and a DCF implying ~36% below cash-flow value.
6 min readSTAUB W RICHARD (See Remarks) sold 5,500 shares of IQVIA HOLDINGS INC. (IQV) at $232.68 ($1.28M total) on 2026-08-03.
1 min readPatel Bhavik (See Remarks) sold 1,855 shares of IQVIA HOLDINGS INC. (IQV) at $235.27 ($0.44M total) on 2026-07-31.
1 min readIQVIA (NYSE:IQV) and Medera will collaborate to advance Medera’s Sardocor cardiac AAV-based gene therapy programs and Novoheart mini-Heart human tissue platform. IQVIA will support patient recruitment, data quality and regulatory filings, including expedited FDA designations. Novoheart’s platform has supported IND and Fast Track designations and is expanding under FDA Modernization Act 2.0.
3 min readIQVIA reported Q2 CY2026 results with revenue of $4.37B versus $4.30B estimates and adjusted EPS of $3.15 versus $3.03, with adjusted EBITDA of $994M. Management cited 6% organic growth and strong net new bookings. Full-year revenue guidance was lifted to $17.38B and adjusted EPS to $12.90. Analysts discussed bookings, outsourcing, AI, M&A, and margins.
6 min readFactSet-reported analyst estimates for IQVIA Holdings show the average 12-month price target increased from $272.65 to $275. Forecasts range from $240 to $300. Using the Jul. 31 close, the target implies about 17% upside. The consensus rating remains “Buy” with 20 Buys, 4 Holds, and 0 Sells.
1 min readIQVIA Holdings CEO sold about $26.1 million of stock appreciation rights with a Feb 2027 expiration, while retaining a large share position, according to the filing and article. The company reported Q2 revenue up 8.7% to $4.37B, adjusted EPS up 12.1% to $3.15, and record clinical bookings of $3.15B, raising full-year guidance to $17.475B.
5 min readSherbet Eric (See Remarks) sold 5,000 shares of IQVIA HOLDINGS INC. (IQV) at $249.16 ($1.25M total) on 2026-07-29.
2 min readCherofsky Keriann (See Remarks) sold 558 shares of IQVIA HOLDINGS INC. (IQV) at $245.21 ($0.14M total) on 2026-07-29.
2 min read
